To view this content, you need to sign in.
You should only be asked to sign in once. Not the case? Click here
Register now to access this content and more for free.
Merck to buy VC-backed OncoImmune for $425m
Merck has agreed to acquire OncoImmune, a clinical-stage biopharmaceutical company, for $425 million in cash.
